Injection of anti-IgE antibodies will suppress IgE and allergic symptoms.
Patalano
F
F
Project Management, Novartis Pharma AG, Basel, Switzerland.
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000628:therapy; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D007073:Immunoglobulin E / Q000096:biosynthesis / Q000097:blood*; D006255:Rhinitis, Allergic, Seasonal / Q000628:therapy
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; C026408:anti-IgE antibodies; D007073:Immunoglobulin E